

DARZALEX (daratumumab)

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

Multiple myeloma (MM)

AND ONE of the following:

- 1. Newly diagnosed multiple myeloma (MM) AND ONE of the following:
 - a. Patient is ineligible for autologous stem cell transplant
 - i. Used in combination with **ONE** of the following:
 - 1) Bortezomib, melphalan, and prednisone
 - 2) Lenalidomide and dexamethasone
 - b. Patient is eligible for autologous stem cell transplant
 - i. Used in combination with bortezomib, thalidomide, and dexamethasone
- 2. Used in combination with carfilzomib and dexamethasone
 - a. Patient has received one to three prior lines of therapy
- 3. Used in combination with lenalidomide and dexamethasone
 - a. Patient has relapsed or refractory multiple myeloma **AND** patient has received at least one prior therapy
- 4. Used in combination with bortezomib and dexamethasone
 - a. Patient has received at least one prior therapy
- 5. Used in combination with pomalidomide and dexamethasone
 - a. Patient has received at least two prior therapies that include a proteasome inhibitor (PI) and lenalidomide
- 6. Used as monotherapy **AND ONE** of the following:
 - a. Patient has received at least three prior lines of therapy including a proteasome inhibitor (PI) and immunomodulatory agent



DARZALEX (daratumumab)

 b. Patient has had a double-refractory failure to a proteasome inhibitor (PI) and an immunomodulatory agent

Prior - Approval Limits

Duration 12 months

Prior – Approval Renewal Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

Multiple myeloma (MM)

AND the following:

1. NO disease progression or unacceptable toxicity

Prior - Approval Renewal Limits

Same as above